Karachi, GlaxoSmithkline Pakistan Limitedinformed Pakistan Stock Exchange about the recommendations made by the board of directors in the meeting held at Karachi on January 29, 2018.
The agenda of the meeting was discussion of profit and loss account for quarter ended December 31, 2017 which portrayed a profit of Rs. 706,815 with earnings per share 7.39 basic and diluted respectively.
Further, 50% payment of cash dividend, bonus shares and right shares was agreed.
Furthermore, the share transfer books of the company will remain closed from March23, 2018 to March 29, 2018 (both days inclusive).
Glaxo Smith Kline Pakistan Limited is incorporated in Pakistan as a limited liability company. The company is engaged in manufacturing and marketing of research based pharmaceutical and consumer products. The company is a subsidiary of S.R. One International B.V., Netherlands, whereas its ultimate parent company is GlaxoSmithKline Plc, UK. The stocks of the company are quoted on the Karachi and Lahore Stock Exchanges of Pakistan.
The company was created on January 1, 2001 through the merger of SmithKline and French of Pakistan Limited, Beecham Pakistan Private Limited and Glaxo Wellcome Pakistan Limited. Some of the pharmaceutical brands produced by the company include Augmentin, Seretide, Amoxil, Velosef, Zantac and Calpol and renowned consumer healthcare brands, which include Panadol, Horlicks, Aquafresh, Macleans and ENO.
The symbol “GLAXO” is being used by the stock exchanges for the shares of GlaxoSmithKline Pakistan Limited.